Abstract
Hepatocellular carcinoma (HCC) and variceal bleeding are among the most common causes of liver-related mortality in patients with hepatitis C virus (HCV)-induced cirrhosis. Current guidelines recommend HCC and gastroesophageal varices (GEV) surveillance in patients with HCV infection and cirrhosis. However, since the recent introduction of direct-acting antivirals, most patients with cirrhosis are now cured of their chronic HCV infection. As virological cure is considered to substantially reduce the risk of cirrhosis-related complications, this review discusses the current literature concerning the surveillance of HCC and GEV in patients with HCV-induced cirrhosis with a focus on the setting following sustained virological response.
Original language | English |
---|---|
Pages (from-to) | 6-14 |
Number of pages | 9 |
Journal | European Journal of Internal Medicine |
Volume | 94 |
Early online date | 23 Sept 2021 |
DOIs | |
Publication status | Published - 1 Dec 2021 |
Bibliographical note
Funding Information:Cas J Isfordink follows a PhD traject in the CELINE (hepatitis C elimination in the Netherlands) initiative sponsored by Gilead. Raoel Maan received financial compensation for consultancy from AbbVie. Robert A de Man has nothing to disclose. Karel J van Erpecum participated in advisory boards of Gilead, Janssen-Cilag, BMS, Abbvie, and MSD and received research grants from Gilead, Janssen-Cilag and the DutchCancer Society (KWF Kankerbestrijding). Adriaan J van der Meer received financial compensation for lecture activities from Zambon, research funding from Gilead, MSD, AbbVie and Zambon, and compensation for consultancy from AOP Orphan.
Publisher Copyright:
© 2021